Pelthos Therapeutics Inc. (PTH) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of the 2025 Annual Meeting of Stockholders held by Pelthos Therapeutics Inc. on December 17, 2025. The Company is incorporated in Nevada and its common stock trades on the NYSE American LLC under the symbol PTHS. As of the record date (November 24, 2025), there were 3,086,681 shares of common stock issued and outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance data.
Material Changes and Voting Results
Stockholders present in person or by proxy held 2,528,857 votes, constituting a quorum. The following proposals were voted upon:
- Proposal 1 (Election of Directors): All seven nominees were elected to serve until the 2026 Annual Meeting. Voting was overwhelmingly in favor, with "For" votes ranging from 2,248,962 to 2,250,670 per nominee. There were 278,134 broker non-votes.
- Proposal 2 (Waiver of Share Issuance Limit): Stockholders approved a proposal to waive the limit on the number of shares of Common Stock that may be issued to holders of the Company's senior secured convertible notes, as required by NYSE American LLC. Results: 2,247,248 For, 3,474 Against, 1 Abstain. There were 278,134 broker non-votes.
- Proposal 3 (Ratification of Auditors): Stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Results: 2,509,765 For, 19,091 Against, 1 Abstain. There were 0 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, or contingencies beyond the standard disclosure of the voting process. The approval of Proposal 2 indicates the Company is managing its capital structure regarding senior secured convertible notes.
Key Facts for Investor Verification
- Verify the terms of the senior secured convertible notes referenced in Proposal 2 to understand potential dilution.
- Confirm the composition of the newly elected Board of Directors and their tenure until the 2026 Annual Meeting.
- Review the Definitive Proxy Statement (Schedule 14A) filed on November 25, 2025, for detailed background on the proposals.
- Note the significant number of broker non-votes (278,134) on Proposals 1 and 2, which may indicate shares held in street name where brokers lacked discretionary voting power.